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Abstract
Background: Allergy places a considerable cost burden on society. Specific immunoglobulin E (spIgE) testing may
improve the management of allergy patients. There is therefore a reason to quantify the economic consequences
of the use of spIgE testing in the diagnosis of allergic conditions.
Methods: The expected costs of spIgE testing versus no-testing were calculated using a clinical decision model
based on a prospective clinical trial performed in primary care.
Results: The expected costs per patient over 2 years decreased from 802 euros in the “no-test strategy” to 560
euros in the spIgE “test strategy”. Cost savings persisted even after assumptions about the prevalence of allergy
and the prices of medications were changed. The “test strategy” increased the percentage of patients correctly
diagnosed from 54 to 87%.
Conclusions: spIgE testing of children with respiratory and/or skin problems in primary care in Italy reduces overall
costs to society. These cost savings mostly result from a reduction in the use of medications, particularly
corticosteroids. The study indicates that spIgE testing of all children with respiratory and/or skin symptoms would
be a cost-effective strategy.
Background
Over the past 40 years, the prevalence of atopic disease
has increased, particularly in Western, industrialised
countries; most of the allergy-related morbidity asso-
ciated with the respiratory system is accounted for by
asthma and allergic rhinitis [1]. Importantly, these con-
ditions substantially affect patients’ quality of life [2-4]
placing a large burden on society in terms of both direct
medical expenditure and decreased productivity [5,6]. In
the U.S., the estimated annual cost for asthma is US$14
billion in direct and indirect costs [7]. The total per-per-
son annual costs of asthma in this country average
$4912.00, with direct and indirect costs accounting for
$3180 (65%) and $1732 (35%), respectively. The largest
components within direct costs are pharmaceuticals
[$1605 (50%)], hospital admissions [$463 (15%)] and
non-emergency department ambulatory visits [$342
(11%)] [8]. Such burden, reduced by an appropriate
diagnostic and screening process for allergy aimed to
increase the appropriateness of referrals from primary
care to the specialist level[9,10], is paid for at the social
level either directly by managed care systems or indir-
ectly by households and businesses.
In the managed-care environment of North America
[11], stretched healthcare budgets have to meet the
growing needs and demands of the population as well as
the increasing costs of new drugs, medical devices and
diagnostic tests. Limited health care resources have to
be used efficiently in order to maximise health out-
comes. Assessment of the costs and benefits of different
ways of allocating resources assists decisions for enhan-
cing efficiency. Economic evaluation plays an important
role in pricing and reimbursement decisions made by
agencies such as the Dental and Pharmaceutical Benefits
Agency (TLV) in Sweden and provides important input
for bodies producing guidance for clinical decisions
such as the National Institute for Health and Clinical
Excellence (NICE) in England and Wales and the guide-
line committee of the National Board of Health and
Welfare in Sweden.
* Correspondence: allerg@tin.it
6Child & Maternal Medicine, The Melloni Hospital, Milan, Italy
Full list of author information is available at the end of the article
Zethraeus et al. Italian Journal of Pediatrics 2010, 36:61
http://www.ijponline.net/content/36/1/61 ITALIAN JOURNAL 
OF PEDIATRICS
© 2010 Zethraeus et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.In managed healthcare, where GP reviews of indivi-
dual allergy and asthma patients form the basis for
epidemiological and economic reports [12], selection of
an appropriate allergy diagnostic methodology can play
a significant economic role.
There is currently no all-purpose (or all-setting)
allergy diagnostic method or standard [13]. As a case in
point, a study conducted in The Netherlands showed
that patients with asthma were highly unlikely to be told
whether their condition was allergic or non-allergic, and
very few patients had ever seen an allergist or received
any allergy test [14]. Improved diagnosis and manage-
ment of patients with allergy symptoms in primary care
is therefore essential, but despite the known benefits of
allergy testing, and although it may account for only a
small proportion of total, direct healthcare costs [15],
some physicians still perceive testing as an unnecessary
expense.
The present study was designed as a cost analysis of
specific immunoglobulin E (spIgE) testing in primary
care compared with no-testing of children with respira-
tory and/or skin symptoms by means of a clinical deci-
sion model based on a clinical trial [16]. The cost
comparison was made from a managed healthcare per-
spective and applied in a European primary care setting,
but could easily apply as a template for U.S. - derived
data. The percentage of patients correctly diagnosed was
estimated for the two strategies compared here.
Methods
The clinical trial on which this study was based
The basis for the economic evaluation and the clinical
decision model was a non-randomised clinical trial [16].
This trial investigated the impact of adding spIgE testing
of blood on the current management by primary-care
physicians of children with respiratory and/or skin
symptoms in 721 subjects in Spain and Italy. It was a
prospective one-visit study with no follow-up. All parti-
cipants were informed about the study and signed an
informed consent before participating in the study. The
protocol was reviewed and approved by the Comité Étic
d’Investigació Clinica de la Fundació Jordi Gol i Gurina,
Barcelona on February 28th 2002 (prior to the initiation
of the study).
T h ep r i m a r yo b j e c t i v eo ft h a ts t u d yw a st oe v a l u a t e
the effect of the spIgE test on the frequency of prescrip-
tions for antihistamines, corticosteroids and bronchodi-
lators, and the frequency of advice to avoid allergens.
Secondary objectives were to evaluate the frequency of
referral to an allergist at hospital, of repeat appoint-
ments in primary care, and of diagnostic tests other
than the study tests. The study had a prospective
before/after design and consisted of two parts. In Part I
the results of the spIgE tests were not revealed to the
clinicians before their diagnosis of the patients as aller-
gic, non-allergic or uncertain. In Part II the result of the
spIgE test was known to the diagnosing physician.
Between Parts I and II physicians were given a short
course on blood testing for IgE-mediated allergy, con-
ducted by personnel with special training in the clinical
application of in-vitro allergy testing [16]. The conclu-
sions were that the use of specific IgE antibody determi-
nations improves the clinical management of patients
with allergy-related symptoms in primary care, allowing
advice to be given on specific allergen avoidance.
The “test strategy” o ft h ep r e s e n ts t u d yi n v o l v e dt h e
same clinicians, with a new patient cohort. spIgE antibo-
dies were measured in each patient’s blood using the
ImmunoCAP® analytical system (Phadia AB, Uppsala,
Sweden) including either Phadiatop Infant® (0-5 years of
age) or Phadiatop® and food mix (fx5e) for patients
above the age of 5 years. In accordance with, the tests
the patients were classified as spIgE-positive or spIgE-
negative.
The Italian part of the study included 344 patients in
or referred by ten primary care centres; ten pediatricians
participated. Patient inclusion criteria were age 0-14
years and the presence of at least one of the following
respiratory and skin symptoms at any time during the
previous year: wheezing in the chest, shortness of breath
not correlated with physical exercise, long-standing
cough, itchy throat, recurrent symptoms of cold, recur-
rent sneezing, runny or blocked nose when not having a
cold, eczema, urticaria and angioedema. Patients who
had had an allergy test (skin prick or spIgE) during the
last 12 months, the results of which were known by the
clinician, were excluded, as were patients infected with
human immunodeficiency virus and those with a history
of hepatitis. 194 patients participated in Part I (mean
age 5 years; 57% females; 54% below the age of 5 years),
while 150 patients were included in Part II (mean age
6 years; 55% females; 45% < 5 years). No significant dif-
ferences were found in the distribution of gender and
symptoms between the patient groups in Part I and II.
Different kinds of economic evaluations
An economic evaluation may be classified as cost-benefit
analysis, cost-effectiveness analysis or cost-minimization
analysis. In a cost-benefit analysis, benefits and costs are
measured in monetary units and a treatment is called
cost-effective if the benefits exceed the costs. In a cost-
effectiveness analysis costs are measured in monetary
units and health effects in non-monetary units such as
gained quality-adjusted life-years (QALYs). A treatment
is defined as cost-effective (compared with an alterna-
tive) if the societal value exceeds the costs of a gained
QALY [17]. If the two treatment alternatives under con-
sideration achieve the same health effect or are broadly
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zation analysis is sufficient. In this clinical study no
QALYs of direct relevance for the patient were available:
the only outcome measure was whether a patient was
correctly classified as being allergic or not. If the “test
strategy” found more patients to be correctly diagnosed,
it is reasonable to assume that spIgE testing also
improves quality of life, so that if the total cost of this
strategy is equal to or less than that of no testing, spIgE
testing may be denoted cost-effective.
The clinical decision model and the calculation of
expected costs and outcomes
The expected costs and outcomes for the two strategies,
the “no-test strategy” and the “test strategy”, were calcu-
lated using a clinical decision model (Figure 1) that reflects
12 possible pathways or diagnostic categories, a1t oa12,
and outcomes (e1-e12)[18]. The calculations refer to an
identified child in primary care with respiratory and/or
skin symptoms (Table 1). The path probabilities (p1-p12,
Table 2) of the various final endpoints are based on the
actual distribution of patients in the clinical trial in Italy.
For example, 60% (7.7+52.3) of all patients in the “test
strategy” were diagnosed allergic, whereas the correspond-
ing figure was 70% in the “no-test strategy”. The fraction
of patients having a positive spIgE test-result (prevalence
of allergic sensitization) is assumed to be 0.55. This is
based on the fraction of Italian patients, in Part I and II,
which were classified spIgE positive (190/344). Given the
test result, patients were diagnosed into “uncertain”, “aller-
gic” or “non-allergic” based on the actual distribution of
Italian patients in the clinical trial (Table 2, Figure 1). For
example, the share of patients in the “test strategy” with a
positive test result that were diagnosed allergic was set to
0.95 (87/92, Table 2). The corresponding fraction of
patients in the “no-test strategy” with a positive test result
that were diagnosed allergic was set to 0.81 (79/98).
Definition and estimation of costs and outcomes
The following direct costs were included, based on the
clinical study [16]: medicines (antihistamines, corticos-
teroids and bronchodilators), physician visits in primary
and specialist care at hospital (allergist), and allergy
tests. The educational cost of training and informing
about the principles of spIgE blood testing was not
included in the costs because it was considered to be
protocol-related and may also be expected to be
included in standard medical training. In clinical prac-
tice this cost is probably rather low. The time horizon
in the cost-minimization analysis was set to 2 years. The
reason for this is that the results from spIgE measure-
ments would provide valuable clinical information for
Figure 1 The clinical decision model with different final endpoints and outcomes. Twelve possible diagnostic categories a1t oa12 are
shown. The associated probability p of a patient falling into each category is shown in Table 2, as well as the expected cost per category over 1
and 2 years from initial visit. The outcome, i.e. degree of agreement e between initial allergy test result and the diagnosis assigned (e =1
denotes agreement) is shown in the figure.
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number of medication episodes and the number of phy-
sician visits to primary and specialist care were the same
in year 2 as in year 1. No allergy tests were assumed to
take place in the second year. Costs in the second year
were discounted to present value using a rate of 3%
[17]. All costs are expressed in euros at 2004 prices.
To estimate the costs for each pathway (a1t oa12,
Figure 1), the cost items; mean number of medication
episodes, physician visits and tests were multiplied by
the probability of being in category and the figure of
each cost item respectively and eventually summarized
together (Tables 1 and 2). All quantities were based on
the findings in the clinical trial [16]. If an initial spIgE
test was positive, ten additional spIgE tests were
assumed to be needed during the first year.
The annual costs per patient for allergy medications
are based on the prices from pharmacies in Italy, and
were calculated assuming full medication intake of anti-
histamines (€182 annually; based on ceterezin, 1 tablet/
day and price €9.95 per package of 20 tablets), corticos-
teroids (€730; based on fluticasone, 125-250 mg, 4
puffs/day, and price €40-80 per package of 120 puffs)
and bronchodilators (€64; based on salbutamol and
fenoterol, 100 mg, 4 puffs/day, and price €4.55-5.95 per
package of 120 puffs). The costs per physician and
Table 1 Costs, in the 1
st and 2
nd year and their sum after the initial primary care consultation, of use of medications
and of subsequent physician visits and the average number (n) of courses of medication, further visits and tests
experienced by a patient in each diagnostic category
Cost items Cost (€) year Mean number of episodes in categories a1 to a12
1
st 2
nd sum a1 a2 a3 a4 a5 a6 a7 a8 a9 a10 a11 a12
Initial allergy test 12 12 24 000000 1(0)
e 1(0) 1(0) 1(0) 1(0) 1(0)
Subsequent sIgE tests 8.8 8.5 17.3 000000 10(0) 10(0) 10(0) 0(0) 0(0) 0(0)
Antihistamine use 182
a 177 359 0.56 0.44 0.60 0.43 0.43 0.19 0 0.62 0.50 0 0.20 0.09
Corticosteroids use 730
b 709 1439 0.44 0.38 0.40 0.48 0.37 0.10 0 0.23 0.25 0.67 0 0.11
Bronchodilators use 64
c 62 126 0.11 0.28 0.40 0.33 0.31 0.05 0 0.10 0.25 0 0.10 0.04
Visit Primary care 65 63 128 0.56 0.63 0.60 0.52 0.52 0.29 0 0.60 1 0.33 0.20 0.38
Visit to allergist 65 63 128 0.11 0.24 0 0 0.17 0.05 0 0.32 0.50 0 0.10 0.16
a Based on 1 tablet ceterizin per day for 1 year
b Based on fluticason, 125-250 mg, 4 puffs/day
c Based on salbutamol and fenoterol, 100 mg, 4 puffs/day
dCosts in 2
nd year were discounted to correspond to 1st year (rate:3%)
eNo tests were performed during 2
nd year
Table 2 Strategy, IgE results, physician’s diagnosis, prevalences, frequencies, probabilities and costs in the twelve
possible diagnostics categories, a1 to a12
Category
(no. obs)
Strategy Initial IgE test Physcian’s diagnosis
1Prevalence Observed frequence
2Probability (p)
3Expected category cost
(€)
year 1
4year 2 year 1&2
a1 (9) no-test pos uncertain 0,55 0,09 0,050 24 23 47
a2 (79) no-test pos allergy 0,55 0,81 0,446 192 186 377
a3 (10) no-test pos no-allergy 0,55 0,10 0,055 26 25 52
a4 (21) no-test neg uncertain 0,45 0,22 0,099 48 46 94
a5 (54) no-test neg allergy 0,45 0,56 0,252 105 102 206
a6 (21) no-test neg no-allergy 0,45 0,22 0,099 13 13 26
a7 (1) test pos uncertain 0,55 0,01 0,006 1 0 1
a8 (87) test pos allergy 0,55 0,95 0,523 232 175 408
a9 (4) test pos no-allergy 0,55 0,04 0,022 12 9 21
a10 (3) test neg uncertain 0,45 0,05 0,023 12 12 24
a11 (10) test neg allergy 0,45 0,17 0,077 6 5 10
a12 (45) test neg no-allergy 0,45 0,78 0,351 51 46 97
1frequence of positive results during screening, i.e. positive results in Phadiatop/Padiatop Infant
2calculated from the prevalence and observed frequence of being in category
3calculated as the sum of costs for medications, physician visits and allergy tests adjusted for observed episodes per patient on pathway as given in Table 1 and
probability of being in category.
4costs in 2
nd year were discounted to correspond to 1
st year (rate:3%)
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€65, based on figures from the Italian national health
system, the Servizio Sanitario Nazionale. The Servizio
Sanitario Nazionale reimbursement system for allergy
tests charges €12 for a general atopy test such as Pha-
diatop®, and €8.80 for a spIgE test.
The outcome measure was defined as the fraction of
patients who were “correctly” diagnosed as having or
not having allergy, defined as the agreement between
allergy test result and physicians’ allergy classifications.
Each outcome (e1-e12) in Figure 1 was scored 1 (agree-
ment) or 0 (non-agreement).
Sensitivity analysis
Different prevalences of allergy were reported in Parts I
(51% positive) and II (61% positive) in the clinical trial,
and we took the overall mean, 0.55, as the prevalence in
the initial analysis. However, we assessed the role of pre-
valence in determining costs in a sensitivity analysis by
varying the prevalence between 0 and 100%. A second
sensitivity analysis evaluated the impact on expected
costs of separately changing the costs of medication,
physician visits and allergy tests: each cost was increased
or decreased by 50%.
Results
The expected cost for the “test strategy” was lower com-
pared with the “no-test strategy”. The total (discounted)
cost-savings over a 2-year period was €242 (Table 3).
The cost savings associated with the “test strategy” were
primarily the result of changes in the prescription of
allergy medication. Over the 2-year period, the medica-
tion costs decreased by €305 in the “test strategy” com-
pared with the “no-test strategy”. The costs for primary-
care physician visits were similar for the two strategies.
The “test strategy” also implied cost-savings the first
year estimated at €93. Further, the “test strategy” yielded
a percentage of patients correctly diagnosed as 87%
[derived from Figure 1, nodes a8a n da12, as (0.55*0.95
= 52.3) + (0.45*0.78 = 35) = 87.3%] as opposed to the
no-test strategy, where the yield was 54% [(0.55*0.81 =
44.5 + 0.45*0.22 = 9.9) = 54.4%].
The sensitivity analysis showed that the cost-savings
decrease with a higher prevalence of allergy, or conver-
sely the lower the prevalence, the higher the cost-sav-
ings (Figure 2). The cost savings varied between €220
and €260 if using the prevalence figures of 0.61 and 0.51
respectively, which reflect the two Italian patient groups
in Part II and I in the clinical study. The cost-savings
also persisted after changing the costs of medication,
visits and allergy tests.
Discussion
The results show that spIgE testing of children with
respiratory and/or skin problems on visiting the primary
care physician is a cost-saving strategy. The savings are
largely due to the reduced need for medications such as
antihistamines, bronchodilators, and particularly corticos-
teroids. Initial spIgE testing decreased the average number
of medication episodes over 2 years from 0.85 to 0.76
(11%) for antihistamines, from 0.54 to 0.16 (70%) for
bronchodilators, and from 0.73 to 0.36 (51%) for corticos-
teroids. As shown in Table 2, the proportion of uncertain
and false-positive diagnoses decreased substantially in Part
II compared with Part I. This indicates that diagnostic
categorization could be associated with more appropriate
treatment. However, for medication with bronchodilators,
normally prescribed for wheezing independently of spIgE,
the large decrease was a little unexpected. One explanation
could be that an uncertain diagnosis increase the likeli-
hood of overuse of drugs, in this case bronchodilators.
Another explanation could be that there was a slightly
lower prevalence of wheeze-related symptoms in Part II
than in Part I (48% vs 40%, data not shown). Reduced use
of corticosteroids accounted for 87% of the total savings in
allergy medication.
The spIgE testing also increased the fraction of
patients who were correctly diagnosed. Earlier studies
[19-21] have shown similar outcomes regarding diagno-
sis. When patients with allergy-like symptoms were
diagnosed on the basis of case history and physical
examination alone, only 30-65% received a correct diag-
nosis, a figure that increased to 85-97% if allergy tests
were used.
A full economic evaluation would require a health
outcome measure of direct relevance to the patient
rather than the proxy measure used here, but the higher
fraction of correctly diagnosed patients suggests that
patients’ health outcomes and therefore quality of life
were increased by the test strategy.
Table 3 Expected average costs (€) per patient for the
“no-test” and “test strategy”
Strategy Difference
No-test Test
Total costs year 1 407,07 314,17 -92,90
allergy tests 0 61 60,51
medications 360,69 205,92 -154,77
physician visits 46,38 47,74 1,36
Total costs year 2 395,22 246,27 -148,95
allergy tests 0 0 0,00
medications 350,19 199,92 -150,26
physician visits 45,03 46,35 1,32
Total costs year 1 and 2 802,29 560,44 -241,85
allergy tests 0,00 60,51 60,51
medications 710,88 405,85 -305,03
physician visits 91,41 94,08 2,67
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saves costs even if the costs of medications were low-
ered by 50%. A notional 50% decrease in the price of
corticosteroids decreased total cost savings by 55%.
These results are consistent with studies showing that
the cost of medication, in particular corticosteroids, is
more significant than hospitalization costs in patients
with allergy [22,23]. The sensitivity analysis further
showed that the cost savings varied inversely with
the prevalence of allergy. Given a negative spIgE test in
the no-test strategy, physicians more frequently made
the wrong diagnosis than when the spIgE test was posi-
tive. The test strategy increased the percentage of
patients correctly diagnosed from 22 to 78% for a spIgE
negative patient population (Figure 1, nodes a4a n d
a12), and from 81 to 95% for a spIgE positive patient
population (nodes a2 and a7).
The cost analysis was based on clinical data obtained
from an unselected primaryc a r ep o p u l a t i o n ,s ot h e
external validity of the results should be fair. Some lim-
itations of the clinical study should, however, be pointed
out. First, only costs for health care were included. Ide-
ally, a societal perspective should be adopted which also
includes indirect costs such as lost productivity due to
reduced working capacity. European studies of patients
with asthma have shown that, unlike the North-Ameri-
can situation [8], the indirect costs are equal to or even
higher than the direct costs [24,25]. In the case of chil-
dren, parents are hindered in their work situations due
to the need to accompany their child to the primary
care physician. This approach must also include costs of
actions taken by the family in avoiding allergens. Second,
the clinical study was a one-visit study with no follow-
u p .I d e a l l y ,w ew o u l dh a v ep r e f e r r e dt of o l l o wt h e
patients during, say, 2 years after the first physician visit
in primary care. Furthermore, the results from this
study reflect a common patient seeking help in the pri-
mary care setting. Differentiating into different allergy
types and/or age classes would demand a much larger
study population than that used in our study. Third,n o
outcome measure of direct relevance for the patient,
such as a measure of the quality of life, was available.
The findings of this study provide support for
evidence-based recommendations for allergy testing in
children. The guidelines state that allergy testing is an
important prerequisite for early identification of infants
at increased risk for later development of allergic
diseases, and for specific allergy treatment [26]. In addi-
tion, it is recommended that all children with persistent,
recurrent or severe allergic symptoms, or who need con-
tinuous treatment, should be tested for allergy, regardless
of the age of the child. To improve decisions on the effi-
cient allocation of resources for allergy testing in primary
care further, randomized studies are needed which exam-
ine the costs and quality of life in a naturalistic setting.
Our findings support the cost-effectiveness of spIgE
measurement for the diagnosis and management of
allergy in clinical practice. It has been suggested that
Figure 2 Cost savings (€) for different assumptions for the prevalence of patients with allergy as judged by the spIgE test.
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interrupt or improve the progression of allergic disease
[27]. Implementing avoidance, which can reduce the
need for medications [28] is impractical if specific aller-
gens have not been identified. If specific IgE results are
positive, the pediatrician can use those results to recom-
mend avoidance of specific allergens or use pharma-
cotherapy to prevent or treat symptoms. On the
contrary, negative results can prevent unnecessary trials
of allergy medication, direct further diagnostic efforts,
and spare the inconvenience of avoidance for patients
who would not benefit [19]. A negative specific IgE
result would prompt the pediatrician to look for other
causes of symptoms. By providing an accurate definitive
diagnosis, specific IgE testing supports early, appropri-
ate, and targeted therapy, greater patient satisfaction,
and better control of costs. These data may prove the
basis for further analysis in various national contexts
with the progress of managed care to improve allergy
and asthma outcomes in children.
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